Prospective evaluation of cetuximab-mediated antibody-dependent cell cytotoxicity in metastatic colorectal cancer patients predicts treatment efficacy

Cancer Immunology Research

Volumn 4, Issue 4, 2016, Pages 366-374

  Trotta, Anna Maria ^a   Ottaiano, Alessandro ^b   Romano, Carmela ^b   Nasti, Guglielmo ^b   Nappi, Anna ^b   De Divitiis, Chiara ^b   Napolitano, Maria ^a   Zanotta, Serena ^a   Casaretti, Rossana ^b   D'Alterio, Crescenzo ^a   Avallone, Antonio ^b   Califano, Daniela ^a   Iaffaioli, Rosario Vincenzo ^b   Scala, Stefania ^a  

^a Molecular Immunology and Immuneregulation Functional Genomics   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FC RECEPTOR IIA; K RAS PROTEIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; FC RECEPTOR; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ALLELE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; NATURAL KILLER CELL; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; CANCER STAGING; COLORECTAL NEOPLASMS; GENETICS; IMMUNOLOGY; METASTASIS; PATHOLOGY; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CETUXIMAB; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTORS, IGG; TREATMENT OUTCOME;

EID: 84978255425     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0184     Document Type: Article

References (50)

1. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
2. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
3. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment ofmetastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
4. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
5. Hildebrandt B, le Coutre P, Nicolaou A, Köble K, Riess H, Dorken B. Cetuximab: appraisal of a novel drug against colorectal cancer. Recent Results. Cancer Res 2007;176:135-43.
6. Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-typemetastatic colorectal cancer. Eur J Cancer 2010;46:1829-34.
7. Schnueriger A, Grau R, Sondermann P, Schreitmueller T, Marti S, Zocher M. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol Immunol 2011;48:1512-7.
8. Taylor RJ, Chan SL, Wood A, Voskens CJ, Wolf JS, Lin W, et al. Fcg;RIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2009; 58:997-1006.
9. Li X, Ptacek TS, Brown EE, Edberg JC. Fcg receptors: structure, function and role as genetic risk factors in SLE. Genes Immun 2009;10:380-9.
10. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47.
11. Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007;39:271-8.
12. Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastatis Rev 2005;2:487-99.
13. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007;67: 11991-9.
14. López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009;58:1853-62.
15. Taylor RJ, Chan SL, Wood A, Voskens CJ, Wolf JS, Lin W, et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2009; 58:997-1006.
16. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, et al. FcgR2A and FcgR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712-8.
17. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of FcRIIa-FcRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27:1122-9.
18. Rodŕguez J, Zarate R, Bandres E, Boni V, Hernandez A, Sola JJ, et al. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur J Cancer 2012;48:1774-80.
19. Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-typemetastatic colorectal cancer. Eur J Cancer 2010;46:1829-34.
20. Yang X, Zhang X, Mortenson ED, Radkevich-Brown O, Wang Y, Fu YX. Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol Ther 2013;21:91-100.
21. Park SJ, Hong YS, Lee JL, Ryu MH, Chang HM, Kim KP, et al. Genetic polymorphisms of FcgRIIa and FcgRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer. Oncology 2012;82:83-9.
22. Paez D, Paré L, Espinosa I, Salazar J, del Rio E, Barnadas A, et al. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy? Cancer Sci 2010;101:2048-53.
23. Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, et al. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Pharmacogenomics J 2014;14:14-9.
24. Calemma R, Ottaiano A, Trotta AM, Nasti G, Romano C, Napolitano M, et al. Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. J Transl Med 2012;10:232-40.
25. Pernot S, Terme M, Voron T, Colussi O, Marcheteau E, Tartour E, et al. Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol 2014;2014:3738-50.
26. Terme M, Fridman WH, Tartour E. NK cells from pleural effusions are potent antitumor effector cells. Eur J Immunol 2013;43:331-4.
27. Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gian T, Sugimachi K. Natural killer cell activity in patients with hepatocellular-carcinoma: a new prognostic indicator after hepatectomy. Cancer 1998;83:58-63.
28. Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frödin JE. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer 2003;105:717-23.
29. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997;79:2320-8.
30. Norris CF, Pricop L, Millard SS, Taylor SM, Surrey S, Schwartz E, et al. Naturally occurring mutation in FcgRIIA: a Q to K127 change confers unique IgG binding properties to the R131 allelic form of the receptor. Blood 1998;91:656-62.
31. Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica 2007;92: 1127-30.
32. Leppers-van de Straat FG, van der Pol WL, Jansen MD, Sugita N, Yoshie H, Kobayashi T, et al. A novel PCR-based method for direct Fcg-receptor IIIa (CD16) allotyping. J Immunol Methods 2000;242:127-32.
33. WuJ, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcgRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-70.
34. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, et al. Increased natural killer cell expression of CD16, augmented binding andADCC activity to rituximab among individuals expressing the FcgRIIIa-158 V/V and V/F polymorphism. Blood 2007;110: 2561-4.
35. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH. Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 1997;208:151-8.
36. Skehan P, Storeng R, ScudieroD,MonksA,McMahon J, Vistica D, et al.New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer 1990;82:1107-12.
37. Skehan P. Assays of cell growth and cytotoxicity. In: Studzinski GP, editor. Cell growth and apoptosis: a practical approach. New York: Oxford University Press; 1995. p. 169.
38. Oppenheim DE, Spreafico R, Etuk A, Malone D, Amofah E, Peña-Murillo C, et al. Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. Br J Cancer 2014;110:1221-7
39. Bland JM, Altman DG: Statistical-methods for assessing agreement between 2 methods of clinical measurement. Lancet 1986;1:307-10.
40. Taylor RJ, Saloura V, Jain A, Goloubeva O, Wong S, Kronsberg S, et al. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. Cancer Immunol Res 2015;3:567-74.
41. Peeters M, Douillard JY, Van CutsemE, Siena S, Zhang K, Williams R, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013;31:759-65.
42. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-75.
43. Adelstein BA, Dobbins TA, Harris CA, Marschner IC, Ward RL. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. Eur J Cancer 2011;47: 1343-54.
44. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812-20.
45. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractorymetastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62
46. Seo Y, Ishii Y, Ochiai H, Fukuda K, Akimoto S, Hayashida T, et al. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer. Oncol Rep 2014;31:2115-22.
47. Douillard JY, Siena S,Cassidy J, Tabernero J, Burkes R, BarugelM, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25:1346-55.
48. Stintzing S, Stremitzer S, Sebio A, Lenz HJ. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. Hematol Oncol Clin North Am 2015; 29:43-60.
49. Correale P, Botta C, Cusi M, Del Vecchio MT, De Santi MM, Gori Savellini G, et al. Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer 2012; 130:1577-89.
50. Zhuang H, Xue ZY, Wang L, Li XY, Zhang N, Zhang RX. Efficacy and immune mechanisms of cetuximab for the treatment of metastatic colorectal cancer. Clin Oncol Cancer Res 2011;8:207-14.